... set up a bio-analytical laboratory in San Diego, California. It also intends to fund the acquisition of contract research organization companies. WuXi shares will begin trading in Hong Kong on Dec. 1 ...More
EJ Insight2018-12-07
... hangsheng Bio-technology (002680.CN), the company at the center of a nationwide vaccine safety scandal that faces the risk of delisting. A “special treatment” stock, Changsheng rose the maximum 5 perc ...More
EJ Insight2018-11-16
... the Earth BioGenome Project (EBP) as “the next moonshot for biology” after the Human Genome Project, a 13-year, US$3 billion endeavor to map human DNA which was completed in 2003. The EBP is expected ...More
EJ Insight2018-11-02
... Cambridge Bio-Augmentation Systems (CBAS) is working on a "prosthetic interface device" (PID), a neural interface that is integrated into the bone, the skin and the nervous system. Out from the end of ...More
EJ Insight2018-11-01
... tors were biotechnology, up 15.4 percent, petrochemicals with 13.8 percent growth, and electronics and IT, up 11.6 percent. Output of high-tech companies rose 15.9 percent. Actual foreign investment i ...More
EJ Insight2018-09-03
... hangsheng Bio-technology Co. Ltd. of selling 252,600 doses of ineffective DPT vaccines to inoculate children against diphtheria, whooping cough and tetanus, Reuters said. Xinhua said on Wednesday furt ...More
EJ Insight2018-08-16
In mid-July, China's state drug administration ordered Changsheng Bio-technology, a company headquartered in Changchun in northeastern China, to stop production of rabies vaccines after it uncovered e ...More
EJ Insight2018-08-16
... hangsheng Bio-technology, a company headquartered in Ch ...全文
今日信報時事評論EJ InsightFrank Ching2018年08月16日
... hangsheng Bio-technology Ltd. (002680.CN), which was found to have falsified reports about the production and inspection of some 113,000 rabies vaccines, according to the China Food and Drug Administr ...More
EJ Insight2018-07-24
... first is bio-tech companies that have not established a track record of revenues and profits, which is currently required by the exchange’s financial eligibility rules. The second is high-growth inno ...More
EJ Insight2018-03-02
